Related Experiment Video
Updated: Jun 23, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
[Second-line chemotherapy for colorectal cancer]
Yoshito Komatsu1, Susumu Sogabe, Yasuyuki Kawamoto
1Hokkaido University Hospital Cancer Center, Sapporo, Japan.
Abstract:
For the current metastatic colorectal cancer, FOLFIRI or FOLFOX is chosen as first-line chemotherapy. Second-line irinotecan-based chemotherapy is commonly used after first-line oxaliplatin-based chemotherapy. Of course, FOLFOX becomes the second-line if FOLFIRI becomes primary therapy. It is important that these regimens combine molecular targetting agents such as Bevacizumab or Cetuximab. The addition of these new agents offers a chance to further enhance the activity of conventional chemotherapy.
More Related Videos
06:21Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
Endoscopic Procedures II: Colonoscopy
Treatment Resistent Cancers
Treatment Resistant Cancers
Drugs for Treatment of Ulcerative Colitis in IBD
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists